Status message

Not the entire site translated, but only to "Journal"

THE ROLE OF MODERN PROLONGED ANTIBIOTICS IN THE EARLY STAGES OF SCHIZOPHRENIA

Petrova Nataliia
Saint-Petersburg State University, Saint-Petersburg, Russia

ANNOTATION.
The review article presents the clinical and pathogenetic characteristics of the first episode of schizophrenia, describes the features of the therapeutic response and adherence to therapy in these patients. Nonadherence to medication in patients withearly schizophrenia is one of the main causes leading to an adverse outcome, while the use of prolonged forms of antipsychotics can significantly increase patients’ compliance and, accordingly, significantly affect the overall effectiveness of long-term anti-relapse therapy.The expediency of long-term anti-relapse antipsychotic therapy is substantiated, data on the use of injectable prolonged antipsychotics in the early stages of schizophrenia are presented.

Contact: petrova_nn@mail.ru

References: 

1. Wójciak P., Remlinger-Molenda A., Rybakowski J. Stages of the clinical course of schizophrenia-staging concept // J Psychiatr Pol. – 2016. – Vol. 50, No. 4. – P. 717–730. – DOI: 10.12740/PP/58723
2. Martinuzzi E., Barbosa S., Daoudlarian D. et al. Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study // Translational Psychiatry. – 2019. – Vol. 9. – R. 171. – DOI: 10.1038/s41398-019-0505-7
3. Mosolov S.N., Tsukarzi E.E. Psikhofarmakoterapiya shizofrenii // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M., 2018. – S. 299–328.
4. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Mosolov S. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia. Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance // World J Biol Psychiatry. – 2012. – Vol. 13 (5). – P. 318–378.
5. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu shizofrenii. Proekt 07.11.2013. Obsuzhdenie na saite Rossiiskogo obshchestva psikhiatrov psychiatr.ru.
6. Reed G.M., First M.B., Kogan C.S. et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders // World Psychiatry. – 2019. – Vol. 18, No. 1. – P. 3–19. – DOI: 10.1002/wps.20611
7. Kulygina M.A., Krasnov V.N. O provedenii polevykh ispytanii novoi versii mezhdunarodnoi statisticheskoi klassifikatsii boleznei i problem, svyazannykh so zdorov'em // Rossiiskii psikhiatricheskii zhurnal. – 2018. – № 3. – S. 4–9.
8. Rais M., Cahn W., Schnack H.G. et al. Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient // Psychol Med. – 2012. – Vol. 42. – P. 1847–1856.
9. Kahn R S, Sommer I E .The neurobiology and treatment of first – episode schizophrenia //Mol Psychiatry. – 2015. – Vol. 20, No. 1. – R. 84–97.
10. Huang M. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia // BMC Psychiatry. – 2016. – Vol. 16, No. 1. – R. 344.
11. Anderson K.K., Voineskos A., Mulsant B.H. The role of untreated psychosis in neurodegeneration: a review of hypothesized mechanisms of neurotoxicity in first-episode psychosis // Can J Psychiatry. – 2014. – Vol. 59 (10). – P. 513–517.
12. First-episode psychosis is a ‘brain attack,’ and LAIs can prevent recurrence, expert says // Frontline Medical News. – 2017. – Available at: https://www.mdedge.com/psychiatry/article/107416/schizophrenia-other-psy... psychotic-disorders (accessed November 12, 2019).
13. Bugarski-Kirola D. Future prospects in the treatment of negative symptoms // European Archives of Psychiatry. Clin Neuroscience. – 2013. – Vol. 263, No. 1. – R. 23.
14. Penttilä M., Jääskeläinen E., Hirvonen N., Isohanni M., Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: a systematic review and meta-analysis // Br J Psychiatry. – 2014. – No. 205. – R. 88–94.
15. Kane J.M. Treatment strategies to prevent relapse and encourage remission // J Clin Psychiatry. – 2007. – No. 68 (Suppl. 14). – R. 27–30.
16. Karson C., Duffy R.A., Eramo A. et al. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review // Neuropsychiatric Disease and Treatment. – 2016. – No. 12. – R. 57–67. DOI: 10.2147/NDT.S96392
17. Zipursky R.B., Menezes N.M., Streiner D.L. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review // Schizophr Res. – 2014. – No. 152. – R. 408–414.
18. Gaebel W., Riesbeck M., Wölwer W. et al. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: Results of a randomized controlled trial within the German Research Network on Schizophrenia // J Clin Psychiatry. – 2011. – Vol. 72, No. 2. – R. 205–218. –DOI: 10.4088/JCP.09m05459yel
19. Nasrallah H., Tandon R., Keshavan M. Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment // Epidemiol Psychiatr Sci. – 2011. – No. 20. – R. 317–327.
20. Krasnov V.N., Gurovich I.Ya., Mosolov S.N., Shmukler A.B. Psikhiatricheskaya pomoshch'. Klinicheskoe rukovodstvo. – M.: Medpraktika, 2007. – 260 s.
21. Mayoral-van Son J., de la Foz V.O., Martinez-Garcia O. et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study // J Clin Psychiatry. – 2016. – Vol. 77, No. 4. – R. 492–500. – DOI: 10.4088/JCP.14m09540
22. García S., Martínez-Cengotitabengoa M., López-Zurbano S. et al. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review // J Clin Psychopharmacol. – 2016. – Vol. 36, No. 4. – R. 355–371. – DOI: 10.1097/JCP.0000000000000523
23. Chien W.T., Mui J., Gray R., Cheung E. Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial // BMC Psychiatry. – 2016. – Vol. 16, No. 3. – R. 42. – DOI: 10.1186/s12888-016-0744-6
24. Petrova N.N., Tsyrenova K.A. Otsenka priverzhennosti antipsikhoticheskoi terapii u patsientov s pervym epizodom shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2019. – № 3. – C. 2–12.
25. Takeuchi H., Siu C., Remington, G. et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia // Neuropsychopharmacology. – 2019. – Vol. 44, No. 6. – P. 1036–1042. – DOI: 10.1038/s41386-018-0278-3
26. Takeuchi H., Thiyanavadivel S., Agid O., Remington G. Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis // Schizophrenia Research. – 2018. – No. 193. – R. 29–36.
27. Velligan D.I., Wang M., Diamond P. et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications // Psychiatr Serv. – 2007. – No. 58. – R. 1187–1192.
28. Mosolov S.N. Protivoretsidivnaya terapiya bol'nykh shizofreniei. pochemu vazhno nachinat' ee na rannikh etapakh zabolevaniya? // Psikhicheskoe zdorov'e cheloveka i obshchestva. Aktual'nye mezhdistsiplinarnye problemy Nauchno – prakticheskaya konferentsiya: sb. mater. / pod red. G.P. Kostyuka. – M., 2018. – S. 286–306.
29. Abdel-Baki A., Ouellet-Plamondon C., Malla A. Pharmacotherapy challenges in patients with first-episode psychosis // J Affect Disord. – 2012. – No. 138, Suppl. – R. 3–14. – DOI: 10.1016/j.jad.2012.02.029
30. Masand P.S., Roca M., Turner M.S., Kane J.M. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review// Prim Care Companion J Clin Psychiatry. – 2009. – Vol. 11, No. 4. – R. 147–154. – DOI: 10.4088/PCC.08r00612
31. Weiden P.J., Schooler N.R., Weedon J.C., Elmouchtari A., Sunakawa-McMillan A. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study // J Clin Psychiatry. – 2012. – Vol. 73, No. 9. – R. 1224–1233. – DOI: 10.4088/JCP.11m06905
32. Perkins D., Hamer R.M., Johnson J.L., Zipursky R.B. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode // Schizophrenia Research. – Vol. 83, No. 1. –R. 53–63. – DOI: 10.1016/j.schres.2005.10.016
33. Ochoa S., López-Carrilero R. Early psychological interventions for psychosis // World J Psychiatry. – 2015. – Vol. 5, No. 4. – R. 362–365. – DOI: 10.5498/wjp.v5.i4.362
34. Reddy K.S., Thirthalli J., Kumar C.N. et al. Treatment Discontinuation in Schizophrenia: A Qualitative Exploration from a Rural South Indian Community // J Neurosci Rural Pract. – 2017. – Vol. 8, No. 2. – R. 254–260. – DOI: 10.4103/0976 – 3147.203809
35. Ayesa-Arriola R., Moríñigo J.D., David A.S. et al. Lack of insight 3 years after first-episode psychosis: an unchangeable illness trait determined from first presentation? // Schizophr Res. – 2014. – Vol. 157, No. 1–3. R. 271–277. – DOI: 10.1016/j.schres.2014.05.011
36. Petrova N.N., Tsyrenova K.A. Komplaens i kognitivnoe funktsionirovanie patsientov s pervym epizodom shizofrenii // Rossiiskii psikhiatricheskii zhurnal. – 2019. – № 4. – S. 36–41. DOI: 10.24411/1560-957X-2019-11934
37. Kane J.M., Kishimoto T., Correll C.U. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies // World Psychiatry. – 2013. – No. 12. – R. 216–226.
38. Hasan A., Falkai P., Wobrock T. et al. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies for biological treatment of schizophrenia. Part 2: update 2012 on the longterm treatment of schizophrenia and management of antipsychotic-induced side effects // World J Biol Psychiatry. – 2013. – No. 14. – R. 2–44.
39. Kane J.M., García-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections // Br J Psychiatry. – 2009. – No. 195. – R. 63–67.
40. Sacchetti E., Grunze H., Leucht S., Vita A. Long-acting injection antipsychotic medications in the management of schizophrenia // Evid Based Psychiatry Care. – 2015. – No. 1. – R. 27–36.
41. Spanarello S., La Ferla T. The pharmacokinetics of long-acting antipsychotic medications // Curr Clin Pharmacol. – 2014. – Vol. 9, No. 3. – R. 310–317.
42. Brissos S., Veguilla M.R., Taylor D., Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal // Therapeutic Adv Psychopharm. – 2014. – Vol. 4, No. 5. – R. 198–219. – DOI: 10.1177/2045125314540297
43. De Berardis D., Serroni N., Olivieri L. May second generation long-acting injectable antipsychotics be prescribed as a first-line treatment of first episode in patients with schizophrenia? An overview // Research and Advances in Psychiatry. – 2015. – Vol. 2, No. 2. – R. 48–58.
44. Stevens G.L., Dawson G., Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia // Early Interv Psychiatry. – 2016. – Vol. 10, No. 5. – R. 365–377.
45. Lyubov E.B., Poteshkin N.M., Alekseev S.V. i soavt. Klinicheskaya i sotsial'naya effektivnost' lecheniya shizofrenii paliperidonom pal'mitatom (Kseplionom) // Sotsial'naya i klinicheskaya psikhiatriya. – 2015. – T. 25, № 1. – S. 59–66.
46. Mosolov S.N., Potapov A.V., Tsukarzi E.E. Standartizirovannye kliniko-funktsional'nye kriterii terapevticheskoi remissii pri shizofrenii: metodich. ukazaniya. – M.: FGBU «NMITsPN im. V.P. Serbskogo» MZ RF, 2017. – 73 s.
47. Correll C.U., Citrome L., Haddad P.M. et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence // J Clin Psychiatry. – 2016. – No. 77, suppl. l3. – R. 1–24.
48. Olayinka O., Oyelakin A., Cherukupally K. et al. Use of long-acting injectable antipsychotic in an inpatient unit of a Community teaching hospital // Psychiatry Journal. –Vol. 2019, Art. ID 8629030. – 5 p. – DOI: 10.1155/2019/8629030
49. Barnes T.R. Schizophrenia Consensus Group of British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology // J Psychopharmacol. – 2011. – Vol. 25. – P. 567–620.
50. National Institute for Health and Clinical Excellence (NICE) Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). Final version (NICE Clinical Guideline 82). NICE. – London, 2009. – Available at: http://www.nice.org.uk/CG82 (accessed November 11, 2019).
51. Tiihonen J., Haukka M, Taylor P. et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia // American Journal of Psychiatry. – 2011. – Vol. 168, No. 6. – R. 603–609.
52. Kishi T., Oya K., Iwata N. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trials // Pychiatry Res. – 2016. – No. 246. – R. 750–755.
53. Cervone A., D’Onghia A., Ferrara M., Massaro C.R. M. Efficacy of lAI in first episode psychosis: an observational study-clinical reports // Psychiatria Danubina. – 2015. – Vol. 27, Suppl. 1. – R. 348–352.
54. Abdel-Baki A., Thibault D., Medrano S. et al. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder // Early Interv Psychiatry. – 2019, May 24. – DOI: 10.1111/eip.12826
55. Bridges J.F., Beusterien K., Heres S. et al. Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling // Patient Prefer Adherence. – 2018. – No. 12. – R. 63–70. – DOI: 10.2147/PPA.S152870
56. Parellada E., Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia // CNS Drugs. – 2016. – Vol. 30, No. 8. – R. 689–701. – DOI: 10.1007/s40263-016-0350-7
57. Yeo S.U., Park J.I., Jang J.M. et al. Acceptance rate of long-acting injection after short information: a survey in patients with first- and multiple-episode psychoses and their caregivers // Early Interv Psychiatry. – 2017. – Vol. 11, No. 6. – R. 509–516. – DOI: 10.1111/eip.12262
58. Salgueiro M., Segarra R. Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review // International Clinical Psychopharmacology. – 2019. – Vol. 34, No. 2. – R. 51–56. –DOI: 10.1097/YIC.0000000000000249
59. Petric´ D., Racˇki V., GacˇN. et al. Retrospective analysis of the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients // Journal of Child and Adolescent Psychopharmacology. – 2019. – Vol. 29, No. 3. – R. 197–204. – DOI: 10.1089/cap.2018.0044
60. Faden J. How do we select an antipsychotic for those with schizophrenia? Expert Opinion on Pharmacotherapy. – 2019. – No. 1. – R. 1–5. – DOI: 10.1080/14656566.2019.1674284
61. Petrova N.N., Kucher E.O. Preparaty prolongirovannogo deistviya v podderzhivayushchei terapii bol'nykh s pervym psikhoticheskim epizodom // Sotsial'naya i klinicheskaya psikhiatriya. – 2014. – T. 24, № 3. – S. 67 – 72.
62. Lyubov E.B. In"ektsionnye antipsikhotiki dlitel'nogo deistviya pri pervom epizode shizofrenii: klinicheskaya perspektiva (analiticheskii obzor) // Rossiiskii psikhiatricheskii zhurnal. – 2013. – № 6. – S. 59–69.
63. Lyubov E.B. Farmakoekonomicheskii analiz deponirovannykh in"ektsionnykh form atipichnykh antipsikhotikov pri lechenii shizofrenii // Sotsial'naya i klinicheskaya psikhiatriya. – 2014. – T. 24, vyp. 1. – S. 101–105.
64. Subotnik K.L., Casaus L.R., Ventura J. et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial // JAMA Psychiatry. – 2015. – No. 72. – R. 822–829.
65. Weiden P.J., Schooler N.R., Weedon J.C. et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome // J Clin Psychiatry. – 2009. – No. 70. – R. 1397–1406.
66. Kim B., Lee S.H., Choi T.K. et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting // Prog Neuropsychopharmacol Biol Psychiatry. – 2008. – No. 32. – R. 1231–1235.
67. Dibonaventura M., Gabriel S., Dupclay L. et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia // BMC Psychiatry. – No. 12. – R. 20.
68. Emsley R., Oosthuizen P., Koen L. et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection // Int Clin Psychopharmacol. – 2008. – No. 23. – R. 325–331.
69. Jeong H.G., Lee M.S. Long-acting injectable antipsychotics in first-episode schizophrenia // Clin Psychopharmacol Neurosci. – 2013. – Vol. 11, No. 1. – R. 1–6. – DOI: 10.9758/cpn.2013.11.1.1
70. Neznanov N.G., Shmukler A.B., Kostyuk G.P., Sofronov A.G. Pervyi psikhoticheskii epizod: epidemiologicheskie aspekty organizatsii pomoshchi // Sotsial'naya i klinicheskaya psikhiatriya. – 2018. – T. 28, № 3. – S. 5–11.
71. Altamura A., Aguglia E., Bassi M. et al. Rethinking the role of long-acting atypical antipsychotics in the community setting // Int Clin Psychopharmacol. – 2012. – No. 27. – R. 336–349.
72. Bartzokis, G., Lu, P., Amar, P. et al. Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory// Schizophr Res. – 2011. – №132. – R. 35–41.
73. Olivares J., Pinal B., Cinos C. Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia // Neuropsychiatry. – 2011. – No. 1. – R. 275–289.